iTeos Therapeutics, Inc. to Post Q1 2022 Earnings of $0.96 Per Share, SVB Leerink Forecasts (NASDAQ:ITOS)

iTeos Therapeutics, Inc. (NASDAQ:ITOSGet Rating) – Investment analysts at SVB Leerink dropped their Q1 2022 earnings per share estimates for iTeos Therapeutics in a research note issued to investors on Monday, May 9th. SVB Leerink analyst D. Graybosch now anticipates that the company will earn $0.96 per share for the quarter, down from their previous forecast of $1.07. SVB Leerink also issued estimates for iTeos Therapeutics’ Q2 2022 earnings at $0.94 EPS.

Separately, Zacks Investment Research lowered iTeos Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 26th.

Shares of ITOS opened at $23.35 on Tuesday. iTeos Therapeutics has a one year low of $17.43 and a one year high of $52.43. The stock has a market capitalization of $829.28 million, a PE ratio of 4.16 and a beta of 1.94. The stock’s 50 day moving average price is $32.60.

In other news, insider Joanne Jenkins Lager sold 3,500 shares of the company’s stock in a transaction on Friday, February 11th. The stock was sold at an average price of $35.85, for a total value of $125,475.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Boxer Capital, Llc sold 575,201 shares of the company’s stock in a transaction on Thursday, March 17th. The shares were sold at an average price of $35.25, for a total value of $20,275,835.25. The disclosure for this sale can be found here. Insiders have sold 886,638 shares of company stock worth $29,248,373 in the last three months. 3.95% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in ITOS. RTW Investments LP lifted its stake in iTeos Therapeutics by 37.1% during the 3rd quarter. RTW Investments LP now owns 2,353,015 shares of the company’s stock worth $63,531,000 after acquiring an additional 636,430 shares in the last quarter. BlackRock Inc. lifted its stake in iTeos Therapeutics by 3.5% during the 4th quarter. BlackRock Inc. now owns 1,613,228 shares of the company’s stock worth $75,111,000 after acquiring an additional 54,992 shares in the last quarter. EcoR1 Capital LLC lifted its stake in iTeos Therapeutics by 25.8% during the 3rd quarter. EcoR1 Capital LLC now owns 1,303,157 shares of the company’s stock worth $35,185,000 after acquiring an additional 267,293 shares in the last quarter. Rubric Capital Management LP lifted its stake in iTeos Therapeutics by 18.6% during the 4th quarter. Rubric Capital Management LP now owns 1,172,320 shares of the company’s stock worth $54,583,000 after acquiring an additional 183,637 shares in the last quarter. Finally, Citadel Advisors LLC lifted its stake in iTeos Therapeutics by 2.4% during the 4th quarter. Citadel Advisors LLC now owns 998,941 shares of the company’s stock worth $46,510,000 after acquiring an additional 23,523 shares in the last quarter. 94.71% of the stock is currently owned by institutional investors and hedge funds.

iTeos Therapeutics Company Profile (Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Recommended Stories

Earnings History and Estimates for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.